Tirzepatide vs. Semaglutide: Cost-Effectiveness Modeled for US Obesity Patients
Background
The global epidemic of obesity and overweight conditions poses a significant public health challenge, increasing the risk of numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. Recent advancements in GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists have revolutionized weight management, but the high cost of these therapies raises critical questions about their economic value. This study addresses the knowledge gap regarding the comparative cost-effectiveness of tirzepatide versus semaglutide from a US healthcare payer perspective.
Results
The microsimulation model projected that tirzepatide would be more effective and potentially more cost-effective than semaglutide over a patient's lifetime. Specifically, tirzepatide was associated with an average gain of 0.85 Quality-Adjusted Life Years (QALYs) per patient compared to semaglutide, reflecting superior long-term health outcomes due to greater weight reduction. Although tirzepatide had a higher annual drug acquisition cost, the model indicated that its enhanced efficacy led to a favorable Incremental Cost-Effectiveness Ratio (ICER) of approximately $45,000 per QALY gained when compared to semaglutide, falling below commonly accepted willingness-to-pay thresholds in the US. The study's primary finding was that tirzepatide demonstrated a 2.5-fold higher probability of being cost-effective compared to semaglutide at a willingness-to-pay threshold of $100,000 per QALY. Furthermore, tirzepatide was projected to reduce the incidence of type 2 diabetes by an additional 15% and cardiovascular events by 10% over a 10-year period compared to semaglutide, contributing to overall cost savings in managing these comorbidities.
Why It Matters
This study provides crucial economic evidence for healthcare payers and policymakers in the US, suggesting that the superior efficacy of tirzepatide translates into significant long-term health benefits and a favorable cost-effectiveness profile compared to semaglutide. The implication is that investing in more effective weight loss therapies like tirzepatide could lead to substantial improvements in public health and potentially reduce overall healthcare expenditures related to obesity comorbidities. These findings could directly influence formulary decisions and insurance coverage policies, potentially expanding patient access to advanced obesity treatments. Future steps include real-world evidence studies to validate these model projections and further analyses incorporating broader societal costs and benefits.